<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Seborrheic dermatitis in adolescents and adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Seborrheic dermatitis in adolescents and adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Seborrheic dermatitis in adolescents and adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Denis Sasseville, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Fowler, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H34051752">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis is a chronic, relapsing, and usually mild form of dermatitis that occurs in infants and adults. The severity may vary from minimal, asymptomatic scaliness of the scalp (dandruff) to more widespread involvement. Affected individuals are usually healthy, although seborrheic dermatitis has been associated with human immunodeficiency virus (HIV) infection, Parkinson disease and other neurologic disorders, and use of neuroleptic medications.
        </p>
        <p>
         This topic will discuss the pathogenesis, clinical manifestations, and management of seborrheic dermatitis in adolescents and adults. The infantile form of seborrheic dermatitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16261.html" rel="external">
          "Cradle cap and seborrheic dermatitis in infants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H34051759">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis has a biphasic incidence, occurring in infants between the ages of 2 weeks and 12 months and later during adolescence and adulthood. The prevalence of clinically significant seborrheic dermatitis is approximately 3 percent, with peak prevalence in the third and fourth decades [
         <a href="#rid1">
          1
         </a>
         ]. The actual prevalence is probably much higher when mild cases are included. Males are affected more frequently than females.
        </p>
        <p>
         The prevalence of seborrheic dermatitis is increased among individuals with HIV infection, in whom it may be a presenting sign. The prevalence has been estimated to be around 35 percent among patients with early HIV infection and up to 85 percent among patients with acquired immunodeficiency syndrome (AIDS) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Patients with parkinsonism frequently present with seborrhea (oily skin) and seborrheic dermatitis, both of which may improve with L-DOPA therapy [
         <a href="#rid4">
          4,5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Nonmotor symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H34051766">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of seborrheic dermatitis is not known. Seborrheic dermatitis is not a disease of the sebaceous glands nor is the rate of sebum excretion increased in patients with seborrheic dermatitis [
         <a href="#rid6">
          6
         </a>
         ]. Nonetheless, sebaceous glands appear to be involved in the development of seborrheic dermatitis as indicated by the predilection for body sites with increased numbers of sebaceous glands and larger sebaceous glands (face, scalp, upper trunk, external auditory meatus, and anogenital area). In addition, the infantile form is common early in the first year of life, when androgen-producing, enlarged, neonatal adrenal glands and transplacental transfer of maternal androgens stimulate the growth of the infant's sebaceous glands.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Malassezia
          </em>
         </strong>
         <strong>
          colonization
         </strong>
         –
         <strong>
         </strong>
         Sebaceous glands may play a permissive role in the pathogenesis of seborrheic dermatitis, possibly by creating a favorable milieu for the growth of fungi of the genus
         <em>
          Malassezia
         </em>
         . The lipid-dependent
         <em>
          Malassezia
         </em>
         (formerly known as
         <em>
          Pityrosporum ovale
         </em>
         ) is a saprophyte of normal skin that thrives at the sites of predilection for seborrheic dermatitis [
         <a href="#rid7">
          7,8
         </a>
         ]. The use of molecular markers, such as 26S rDNA, ITS, and 5.8S, has allowed for better species identification and revealed intraspecies differences that could be related to pathogenicity [
         <a href="#rid9">
          9,10
         </a>
         ]. However, there is limited direct evidence that
         <em>
          Malassezia
         </em>
         is implicated in the etiology of seborrheic dermatitis. Studies have failed to demonstrate a higher density of
         <em>
          Malassezia
         </em>
         on the skin of affected individuals or a relationship between the intensity of skin colonization and the severity of seborrheic dermatitis, although some specific
         <em>
          Malassezia
         </em>
         species have been detected more frequently on affected skin than on nonaffected skin [
         <a href="#rid11">
          11-13
         </a>
         ]. A higher density of
         <em>
          Malassezia
         </em>
         has been demonstrated in patients with Parkinson disease and seborrheic dermatitis compared with controls, with a predominance of
         <em>
          Malassezia globosa
         </em>
         displaying high production of lipases and phosphatases [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Indirect evidence for a role of
         <em>
          Malassezia
         </em>
         in seborrheic dermatitis derives from the observation that most of the effective therapeutic agents have antifungal activity. However, the nonspecific, anti-inflammatory effect of the azole antifungal agents commonly used for seborrheic dermatitis may also explain their efficacy, given that some studies have been unable to demonstrate in vivo a decrease in
         <em>
          Malassezia
         </em>
         colonization after treatment with topical
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Observational studies suggest that, in some patients, seborrheic dermatitis may result from the host's immune response to
         <em>
          Malassezia
         </em>
         or to its byproducts [
         <a href="#rid16">
          16,17
         </a>
         ]. Other studies, however, were unable to find humoral or cellular immunologic abnormalities in patients with seborrheic dermatitis [
         <a href="#rid18">
          18
         </a>
         ]. The inflammation of seborrheic dermatitis may be mediated by the innate immune system response to irritants produced by
         <em>
          Malassezia
         </em>
         , including free fatty acids, lipase, and reactive oxygen species [
         <a href="#rid16">
          16
         </a>
         ]. The lipases and phospholipases produced by
         <em>
          Malassezia
         </em>
         cleave free fatty acids from triglycerides present in sebum, which are known irritants and can induce inflammation. In addition, lipases and phosphatases damage surrounding cells with the release of oleic and arachidonic acid from their walls. Arachidonic acid is further metabolized by cyclooxygenase in proinflammatory eicosanoids [
         <a href="#rid14">
          14
         </a>
         ]. Additional factors that may be playing a role in the inflammation of seborrheic dermatitis include oxidative stress and the overproduction of cell-damaging oxygen radicals [
         <a href="#rid19">
          19
         </a>
         ]. The cascade of inflammation leads to the increased production of numerous cytokines ascribed to activation of T lymphocytes of T helper type 2 (Th2) lineage, such as interleukin (IL) 1, 2, 4, 8, and possibly 17; interferon (IFN)-gamma; and tumor necrosis factor (TNF)-alpha [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – The reason for the increased susceptibility of patients with HIV infection to seborrheic dermatitis is not known. A transgenic mouse deficient in CD4+ and CD8+ cells has been shown to develop a seborrheic dermatitis-like skin disease, an overgrowth of yeast cells in hair follicles, and an improvement with
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. This suggests that dysregulation of the immune system may play a role in the increased prevalence of seborrheic dermatitis in the immunocompromised host.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic disorders
         </strong>
         – The relationship between seborrheic dermatitis and neurologic disorders is also poorly understood. Patients with Parkinson disease often have increased sebum production; in these patients, seborrhea and seborrheic dermatitis improve with L-DOPA therapy [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34051773">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis may first appear soon after puberty or later in life. It is usually characterized by well-demarcated, erythematous plaques with greasy-looking, yellowish scales distributed on areas rich in sebaceous glands, such as the scalp, the external ear, the center of the face, the upper part of the trunk, and the intertriginous areas  (
         <a class="graphic graphic_picture graphicRef56410 graphicRef82073 graphicRef59104" href="/z/d/graphic/56410.html" rel="external">
          picture 1A-C
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H498821253">
         <span class="h2">
          Scalp
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mildest and most common form of scalp seborrheic dermatitis is dandruff, also known as pityriasis sicca, in which the scalp shows fine, white, diffuse scaliness without underlying erythema  (
         <a class="graphic graphic_picture graphicRef54173" href="/z/d/graphic/54173.html" rel="external">
          picture 2
         </a>
         ). Dandruff may be asymptomatic or accompanied by mild pruritus. More severe forms of scalp seborrheic dermatitis present with visible inflammation, consisting of patchy, orange to salmon-colored or grayish plaques covered with yellowish, greasy scales (pityriasis steatoides), mostly over the temporoparietal areas  (
         <a class="graphic graphic_picture graphicRef76985 graphicRef114660" href="/z/d/graphic/76985.html" rel="external">
          picture 3A-B
         </a>
         ) or with concretions of scale around hair shafts (pityriasis amiantacea)  (
         <a class="graphic graphic_picture graphicRef114661" href="/z/d/graphic/114661.html" rel="external">
          picture 3C
         </a>
         ). Lesions may extend to the postauricular areas  (
         <a class="graphic graphic_picture graphicRef82073" href="/z/d/graphic/82073.html" rel="external">
          picture 1B
         </a>
         ), where they often develop fissures, oozing, and crusting, and to the outer canal and concha of the ear, sometimes with marked pruritus and superinfection (otitis externa). (See
         <a class="medical medical_review" href="/z/d/html/6866.html" rel="external">
          "External otitis: Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis and risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H498821260">
         <span class="h2">
          Face
         </span>
         <span class="headingEndMark">
          —
         </span>
         Facial lesions favor the forehead below the hairline, the eyebrows and glabella  (
         <a class="graphic graphic_picture graphicRef114660" href="/z/d/graphic/114660.html" rel="external">
          picture 3B
         </a>
         ), and the nasolabial folds. They may extend to the cheeks and malar areas in a butterfly distribution; depending on a person's skin color, lesions may look pink or red, ashy gray, or darker than normal skin  (
         <a class="graphic graphic_picture graphicRef114634 graphicRef65167 graphicRef59104" href="/z/d/graphic/114634.html" rel="external">
          picture 1C-E
         </a>
         ). The mustache and beard area are frequently involved in patients with facial hair. Shaving helps with treatment and control of the disease.
        </p>
        <p class="headingAnchor" id="H498821267">
         <span class="h2">
          Periocular
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blepharitis with redness of the free margin of the eyelids and yellow crusting between the eyelashes may be the sole manifestation of seborrheic dermatitis or may accompany its more classic distribution. (See
         <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">
          "Blepharitis", section on 'Clinical findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H498821274">
         <span class="h2">
          Trunk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Five patterns of truncal involvement have been described:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moist, erythematous intertrigo of the axillae, inframammary folds, umbilicus, and genitocrural area  (
         <a class="graphic graphic_picture graphicRef53407" href="/z/d/graphic/53407.html" rel="external">
          picture 3D
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The "petaloid pattern," consisting of polycyclic, finely scaly, thin plaques over the sternum or interscapular area
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Annular or arcuate, round to oval, slightly scaly plaques on the trunk, sometimes with hypopigmented central clearing, known as "seborrheic eczematids"
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pityriasiform pattern mimicking pityriasis rosea, comprised of 5 to 15 mm, oval-shaped, scaly lesions distributed along the skin tension lines
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The psoriasiform pattern with larger red, rounded plaques, covered with thicker scales
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H498821343">
         <span class="h2">
          In patients with HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis tends to be more extensive and severe in patients with HIV/AIDS. It sometimes involves unusual sites, such as the extremities, and may be difficult to control [
         <a href="#rid3">
          3,21
         </a>
         ]. Seborrheic dermatitis is frequently observed in patients with CD4 counts &lt;400 cells/microL and is more diffuse and severe in patients with CD4 counts &lt;200 cells/microL [
         <a href="#rid22">
          22,23
         </a>
         ]. It may regress with antiretroviral therapy (ART). However, seborrheic dermatitis may also be a cutaneous manifestation of the immune reconstitution inflammatory syndrome in patients on ART [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome", section on 'Miscellaneous syndromes possibly associated with IRIS'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H498821317">
         <span class="h1">
          CLINICAL COURSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis is a chronic, relapsing condition that may go on for decades. It tends to worsen with stress and during the cold and dry winter months. It tends to improve during the summer months, probably from sun exposure, although it may be precipitated by psoralen plus ultraviolet A (PUVA) therapy [
         <a href="#rid25">
          25
         </a>
         ]. The available treatments do not cure seborrheic dermatitis and must be continued or repeated intermittently to prevent recurrence. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H710057309">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         Biopsy is not routinely necessary but may be indicated when the diagnosis is uncertain. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H34051788">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no uniquely characteristic or pathognomonic histologic features in seborrheic dermatitis. In patients who are HIV negative, histology shows focal parakeratosis in the horny layer of the epidermis; mounds of scale-crusts with pyknotic neutrophils on the lips of dilated, sometimes plugged, follicular ostia; psoriasiform acanthosis; and mild to moderate spongiosis. The dermis harbors a sparse, perivascular, lymphohistiocytic, inflammatory infiltrate. In chronic cases, the histologic picture may be difficult to distinguish from psoriasis, but the presence of even a minimal degree of spongiosis should favor a diagnosis of seborrheic dermatitis.
        </p>
        <p>
         In patients with HIV/AIDS, the histopathologic changes parallel the severity of the disease. Parakeratosis is more widespread, and the epidermis shows necrotic keratinocytes. Spongiosis is less prominent; the inflammatory infiltrate is denser and, in some areas, obliterates the dermoepidermal junction. It contains numerous plasma cells and foci of leukocytoclasis [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H34051795">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of seborrheic dermatitis includes psoriasis, rosacea, tinea versicolor, pityriasis rosea, tinea corporis, secondary syphilis, systemic lupus erythematosus (SLE), and pemphigus foliaceous. Most of these conditions can be distinguished clinically. Syphilis, SLE, and pemphigus foliaceous require laboratory confirmation. Allergic contact dermatitis may also be considered, particularly when the presentation is atypical or pruritus is significant.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psoriasis
         </strong>
         – Psoriasis is the main condition in the differential diagnosis of seborrheic dermatitis in adolescents and adults. Sometimes the two diseases may coexist, and the term "sebopsoriasis" has been given to those cases where the distinction cannot be made. Usually, however, psoriatic lesions are sharply demarcated and erythematous, and the scales are more abundant and silvery white  (
         <a class="graphic graphic_picture graphicRef115750" href="/z/d/graphic/115750.html" rel="external">
          picture 4
         </a>
         ). In most cases, the extensor areas (eg, the elbows and knees) are involved, although the lesions can occur in the body folds (inverse psoriasis)  (
         <a class="graphic graphic_picture graphicRef76200" href="/z/d/graphic/76200.html" rel="external">
          picture 5
         </a>
         ). Characteristic nail changes  (
         <a class="graphic graphic_picture graphicRef66374 graphicRef70962" href="/z/d/graphic/66374.html" rel="external">
          picture 6A-B
         </a>
         ) as well as the presence of arthritis or a positive family history may help establish the diagnosis of psoriasis. (See
         <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">
          "Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rosacea
         </strong>
         – Rosacea is another condition that commonly targets the face and sometimes coexists with seborrheic dermatitis. In contrast with seborrheic dermatitis, rosacea shows a predominance of telangiectasias and papulopustules, with frequent involvement of the nose, malar, and perioral areas and minimal or no scaliness  (
         <a class="graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083" href="/z/d/graphic/77020.html" rel="external">
          picture 7A-E
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">
          "Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic contact dermatitis
         </strong>
         – Allergic contact dermatitis may be suspected in patients with seborrheic dermatitis that does not respond to standard therapy, especially if pruritus is the predominant symptom. Allergic contact dermatitis may occur concurrently or be a complication of seborrheic dermatitis in patients allergic to components of topical medications for seborrheic dermatitis or regular skin and hair care products. Patch testing may be necessary to confirm the diagnosis [
         <a href="#rid26">
          26,27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">
          "Clinical features and diagnosis of allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tinea versicolor
         </strong>
         – On the trunk, petaloid lesions of seborrheic dermatitis may be mistaken for tinea versicolor, which usually lacks erythema  (
         <a class="graphic graphic_picture graphicRef78860" href="/z/d/graphic/78860.html" rel="external">
          picture 8
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4039.html" rel="external">
          "Tinea versicolor (pityriasis versicolor)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pityriasis rosea
         </strong>
         – Pityriasis rosea is distinguished from seborrheic dermatitis by its abrupt onset, presence of a herald patch, and resolution within a few weeks  (
         <a class="graphic graphic_picture graphicRef87124 graphicRef87126" href="/z/d/graphic/87124.html" rel="external">
          picture 9A-B
         </a>
         ). The pityriasiform variant of seborrheic dermatitis should be suspected when lesions appear more progressively, persist for more than three months, and are accompanied by lesions on areas usually spared by pityriasis rosea (the face and intertriginous areas). (See
         <a class="medical medical_review" href="/z/d/html/5665.html" rel="external">
          "Pityriasis rosea", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tinea corporis
         </strong>
         – Annular or arciform seborrheic dermatitis lesions on the trunk can be confused with tinea corporis  (
         <a class="graphic graphic_picture graphicRef76839" href="/z/d/graphic/76839.html" rel="external">
          picture 10
         </a>
         ). Tinea corporis can be ruled out by negative potassium hydroxide (KOH) microscopic examination and negative fungal culture. (See
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea corporis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary syphilis
         </strong>
         – Secondary syphilis, the great imitator, can trigger widespread, pityriasiform or psoriasiform eruptions that can be mistaken for seborrheic dermatitis. Additional signs (eg, palmoplantar and mucosal lesions or peripheral adenopathy) should be looked for, and appropriate serologic testing should be ordered when indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lupus erythematosus
         </strong>
         – Seborrheic dermatitis of the face may be mistaken for the butterfly eruption of acute SLE or the discoid plaques of cutaneous lupus erythematosus  (
         <a class="graphic graphic_picture graphicRef64844 graphicRef75833" href="/z/d/graphic/64844.html" rel="external">
          picture 11A-B
         </a>
         ). The acute eruption of SLE rarely involves the nasolabial sulcus or crosses the bridge of the nose. Discoid lesions exhibit atrophy and sometimes scarring, along with adherent scales that may have "carpet tacking" on their undersurface (spiny projections that plug dilated, follicular openings). Histologic examination and serologic testing for antinuclear autoantibodies should be performed to confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pemphigus foliaceous
         </strong>
         – Pemphigus foliaceous is characterized by erythema, scaling, painful erosions, and crusting that first appear on the face and scalp  (
         <a class="graphic graphic_picture graphicRef60530" href="/z/d/graphic/60530.html" rel="external">
          picture 12A
         </a>
         ) and later involve the chest and back. Histology, direct immunofluorescence, and the measurement of circulating autoantibodies against desmoglein establish the diagnosis. Pemphigus erythematosus of Senear and Usher is a superficial variant of pemphigus foliaceous that is most likely to mimic seborrheic dermatitis. (See
         <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Pemphigus foliaceus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27253022">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antifungal agents (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , other azoles,
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         olamine) are well established in the treatment of seborrheic dermatitis of the scalp and face because of their ability to decrease the population of
         <em>
          Malassezia furfur
         </em>
         on the affected skin and their anti-inflammatory property [
         <a href="#rid28">
          28,29
         </a>
         ]. Topical anti-inflammatory agents (eg, topical corticosteroids, topical calcineurin inhibitors) are also frequently used for seborrheic dermatitis alone or in combination with topical antifungals.
        </p>
        <p class="headingAnchor" id="H2731805797">
         <span class="h2">
          Goal of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis is a chronic condition. The main goal of therapy is to clear the visible signs of the disease and reduce associated symptoms, such as erythema and pruritus. Repeated treatment or long-term maintenance treatment is often necessary. (See
         <a class="local">
          'Prevention of relapse'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1431767">
         <span class="h2">
          Seborrheic dermatitis of the scalp
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis of the scalp is managed with antifungal shampoos, with or without topical corticosteroids, depending on dermatitis severity  (
         <a class="graphic graphic_algorithm graphicRef141494" href="/z/d/graphic/141494.html" rel="external">
          algorithm 1
         </a>
         ). The addition of a shampoo containing a keratolytic agent (eg, salicylic acid) may be helpful for patients with thick scale.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild dermatitis (dandruff)
         </strong>
         – For patients with mild seborrheic dermatitis of the scalp who have diffuse, fine desquamation without inflammation (dandruff), we suggest treatment with an antifungal shampoo. Antifungal shampoos include
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% and
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1% (available by prescription) and
         <a class="drug drug_general" data-topicid="10237" href="/z/d/drug information/10237.html" rel="external">
          zinc pyrithione
         </a>
         1% and
         <a class="drug drug_general" data-topicid="9885" href="/z/d/drug information/9885.html" rel="external">
          selenium sulfide
         </a>
         2.5% shampoo (available over the counter).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate to severe dermatitis
         </strong>
         – For patients with moderate to severe seborrheic dermatitis of the scalp who have scale, inflammation, and pruritus, we suggest treatment with an antifungal shampoo (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo) in combination with a high-potency topical corticosteroid  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ) in a formulation (lotion, spray aerosol, foam, or shampoo) of the patient's choice. Topical corticosteroids can be used daily for two weeks and then intermittently (eg, twice weekly).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use and frequency of medicated shampoos
         </strong>
         – Five to 10 mL of shampoo should be left on for three to five minutes before rinsing off.
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          Ketoconazole
         </a>
         shampoo or other antifungal shampoos should be used two to three times per week for two to four weeks in the initial treatment phase. Subsequently, the use of the medicated shampoo can be reduced to once a week to prevent relapse [
         <a href="#rid30">
          30
         </a>
         ]. Minor adverse effects, such as irritation and/or burning sensation, are common with antifungal shampoo [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients sometimes complain that their shampoo is no longer effective. Given that some strains of
         <em>
          Malassezia
         </em>
         eventually become resistant to azole antifungals [
         <a href="#rid19">
          19
         </a>
         ], it may be wise to effectuate, every few weeks to months, a rotation among shampoos based on different nonazole agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Shampoos containing salicylic acid and
         <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">
          coal tar
         </a>
         have keratolytic properties and may be helpful in softening thick scales [
         <a href="#rid33">
          33,34
         </a>
         ]. Tar shampoos, however, are infrequently used as patients may find the odor of tar objectionable or be concerned about its potential carcinogenicity [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3168725797">
         <span class="h2">
          Nonscalp seborrheic dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of nonscalp seborrheic dermatitis is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141495" href="/z/d/graphic/141495.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3408090107">
         <span class="h3">
          Seborrheic dermatitis of the face
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with seborrheic dermatitis of the face, we suggest treatment with a low-potency topical corticosteroid cream (groups 6 or 7  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )), a topical antifungal agent (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% cream, other azole creams,
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1% cream  (
         <a class="graphic graphic_table graphicRef76148" href="/z/d/graphic/76148.html" rel="external">
          table 2
         </a>
         )), or a combination of the two as first-line treatment  (
         <a class="graphic graphic_algorithm graphicRef141495" href="/z/d/graphic/141495.html" rel="external">
          algorithm 2
         </a>
         ). In patients with mild seborrheic dermatitis with minimal erythema and pruritus, we prefer to use topical antifungals alone. In patients with marked erythema and pruritus, we typically start treatment with a low-potency topical corticosteroid until symptoms subside or up to two weeks and then switch to topical antifungals as maintenance treatment. Topical corticosteroids can be used intermittently in case of flare-up.
        </p>
        <p>
         Prolonged daily use (over two weeks) of topical corticosteroids on the face should be avoided due to the risk of local adverse effects (eg, skin atrophy, telangiectasias). (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects"
         </a>
         .)
        </p>
        <p>
         In patients requiring frequent use of topical corticosteroids, topical calcineurin inhibitors (
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.1% ointment and
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         1% cream),
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         2% cream, or
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          roflumilast
         </a>
         0.3% foam may be used as alternative treatments, as they lack adverse effects associated with topical corticosteroids (eg, skin atrophy, telangiectasias) [
         <a href="#rid36">
          36-42
         </a>
         ]. The high cost of topical crisaborole and roflumilast may limit their use.
        </p>
        <p>
         For patients with seborrheic dermatitis of the face who have mustaches and beards, we suggest
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampooing of the facial hair daily until remission and then once per week. A low-potency corticosteroid (group 7  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) can be added to the initial treatment to control inflammation and itching.
        </p>
        <p class="headingAnchor" id="H1666176">
         <span class="h3">
          Seborrheic blepharitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of blepharitis, including seborrheic blepharitis, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">
          "Blepharitis", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H43690682">
         <span class="h3">
          Seborrheic dermatitis of the trunk and intertriginous areas
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with topical antifungal agents, topical corticosteroids, or a combination of the two  (
         <a class="graphic graphic_algorithm graphicRef141495" href="/z/d/graphic/141495.html" rel="external">
          algorithm 2
         </a>
         ). Topical antifungal agents are applied to affected areas once or twice daily until symptoms subside and then continued intermittently to prevent relapses. (See
         <a class="local">
          'Prevention of relapse'
         </a>
         below.)
        </p>
        <p>
         Topical corticosteroids are applied to the affected areas once or twice daily only until symptoms subside to avoid potential adverse effects. A low-potency topical corticosteroid should be used in the intertriginous areas. Medium-potency topical corticosteroids  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ) can be used for seborrheic dermatitis involving the chest or the upper back. For intertriginous areas, topical calcineurin inhibitors can be used as an alternative to topical corticosteroids.
        </p>
        <p class="headingAnchor" id="H1431820">
         <span class="h2">
          Seborrheic dermatitis in patients with HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seborrheic dermatitis is more diffuse and severe in patients who are HIV positive and may require a prolonged course of treatment. There are no studies evaluating the treatment of seborrheic dermatitis in patients who are HIV positive. Initial management is the same as for patients who are not HIV positive [
         <a href="#rid43">
          43,44
         </a>
         ]. In severe cases or in cases that are refractory to topical treatment, a course of oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg/day orally for one week) may be warranted.
        </p>
        <p class="headingAnchor" id="H710057784">
         <span class="h2">
          Severe or refractory seborrheic dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral antifungal agents, including
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         , are a treatment option for seborrheic dermatitis involving multiple body areas and for recalcitrant dermatitis that is not adequately controlled with topical therapies. Among these, we suggest oral itraconazole. Oral itraconazole is given at the dose of 200 mg per day for seven days.
        </p>
        <p>
         Whenever apparent seborrheic dermatitis does not respond to appropriate therapy, the diagnosis should be reconsidered. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3787833205">
         <span class="h2">
          Supporting evidence
         </span>
        </p>
        <p class="headingAnchor" id="H235220125">
         <span class="h3">
          Topical antifungal agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2015 systematic review and meta-analysis that included 51 randomized trials with over 9000 participants found that in patients with seborrheic dermatitis of the face and scalp, topical
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% and
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1% were more effective than placebo in improving erythema, pruritus, and scaling at four weeks [
         <a href="#rid28">
          28
         </a>
         ]. When compared with each other, topical ketoconazole and ciclopirox showed similar efficacy. In studies comparing topical ketoconazole with topical corticosteroids, both agents had similar efficacy, although topical corticosteroids showed a twofold greater risk of side effects compared with ketoconazole [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         However, the included studies used heterogeneous regimens and outcome measurement and were generally of poor methodologic quality.
        </p>
        <p class="headingAnchor" id="H1050268424">
         <span class="h3">
          Topical anti-inflammatory agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical corticosteroids and topical calcineurin inhibitors are widely used for the treatment of seborrheic dermatitis because they reduce inflammation, erythema, and pruritus. Topical
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         sulfate and lithium gluconate (available in Europe but not in the United States) have been shown to be effective in treating seborrheic dermatitis in areas other than the scalp (probably because of their anti-inflammatory properties) [
         <a href="#rid45">
          45-47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – A 2014 systematic review including 36 randomized trials (2706 participants) found that short-term treatment (≤4 weeks) with topical corticosteroids (eg,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         ), topical calcineurin inhibitors (ie,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         ), and topical preparations of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         salts all reduced the symptoms of seborrheic dermatitis when compared with placebo [
         <a href="#rid48">
          48
         </a>
         ]. The median rate of total clearance with anti-inflammatory treatments was 53 percent across studies. The frequency of adverse effects, including erythema, burning, dryness, and itching, was similar across all treatment groups. The quality of the included studies was generally low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical PDE4 inhibitors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          roflumilast
         </strong>
         –
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          Roflumilast
         </a>
         is a selective, highly potent phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory properties. Topical roflumilast 0.3% foam was approved in 2024 by the US Food and Drug Administration (FDA) for the treatment of seborrheic dermatitis in adults and children ≥9 years [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a randomized trial that included 226 adults with seborrheic dermatitis affecting ≤20 percent of the body surface area (BSA) treated with topical
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          roflumilast
         </a>
         0.3% foam or vehicle, more patients in the roflumilast group than in the vehicle group achieved an Investigator Global Assessment (IGA) score of clear/almost clear at eight weeks (74 versus 41 percent, respectively [
         <a href="#rid50">
          50
         </a>
         ]. Treatment was generally well tolerated. Only three adverse events (1.9 percent) in the roflumilast group (ie, application site pain, diarrhea, and insomnia) were deemed to be treatment related. Of note, application site pain is less than with
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         and calcineurin inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Crisaborole
         </strong>
         –
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          Crisaborole
         </a>
         is a boron-based, small molecule, topical PDE4 inhibitor approved for the treatment of mild to moderate atopic dermatitis in adults and children. In a small series of 30 adult patients with mild to moderate facial seborrheic dermatitis, crisaborole 2% cream applied twice daily for four weeks improved all signs of seborrheic dermatitis (erythema, scale, dryness, and pruritus), with 83 percent of patients achieving a "clear or almost clear" IGA score [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2716378439">
         <span class="h3">
          Oral antifungal agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence supporting the use of oral antifungals is limited. A 2014 systematic review including nine uncontrolled, poor-quality studies evaluating oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         for seborrheic dermatitis found that itraconazole was effective in inducing clinical improvement and mycologic cure in 59 to 93 percent and 40 to 86 percent of patients, respectively [
         <a href="#rid52">
          52
         </a>
         ]. The regimen most frequently used involved the oral administration of itraconazole 200 mg per day for seven days followed by varying intermittent therapy for 2 to 11 months.
        </p>
        <p class="headingAnchor" id="H2907239957">
         <span class="h2">
          Coexistent seborrheic dermatitis and rosacea
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with coexistent facial seborrheic dermatitis and rosacea, adequate treatment of both conditions may be difficult. Prolonged use of even mild topical corticosteroids prescribed for seborrheic dermatitis may exacerbate rosacea and should ideally be avoided or used very sparingly and intermittently. By contrast, topical
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         1% gel or cream (used for rosacea) may also help mild seborrheic dermatitis.
        </p>
        <p>
         In patients who have papulopustular rosacea and facial seborrheic dermatitis, topical
         <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">
          azelaic acid
         </a>
         , which has antibacterial and antifungal properties, has been suggested as a treatment option for both conditions [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16632.html" rel="external">
          "Management of rosacea", section on 'Topical azelaic acid'
         </a>
         .)
        </p>
        <p>
         A case report describes the successful use of topical
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         in the treatment of recalcitrant seborrheic dermatitis combined with papular rosacea [
         <a href="#rid54">
          54
         </a>
         ]. Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the inflammatory cascade and decreases the production of T helper type 2 (Th2)-driven cytokines. It is approved for the treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older but has been used off-label to treat other inflammatory skin diseases, such as vitiligo and lichen planus.
        </p>
        <p class="headingAnchor" id="H364614144">
         <span class="h1">
          PREVENTION OF RELAPSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with seborrheic dermatitis, we suggest intermittent use of topical therapies to prevent relapse  (
         <a class="graphic graphic_algorithm graphicRef141494" href="/z/d/graphic/141494.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141495" href="/z/d/graphic/141495.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seborrheic dermatitis of the scalp
         </strong>
         –
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          Ketoconazole
         </a>
         2% shampoo and
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1% shampoo used intermittently (once or twice weekly) have been shown to be effective in preventing relapses of scalp seborrheic dermatitis [
         <a href="#rid30">
          30,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a six-month trial in which 312 patients who responded to initial treatment of scalp seborrheic dermatitis were randomly assigned to
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo once weekly, every two weeks, or placebo, relapses were observed in 19, 31, and 47 percent of the patients, respectively [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a similar study in which 428 patients were randomly assigned to four months of treatment with
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         shampoo once weekly, every two weeks, or placebo, the relapse rates were 15, 22, and 35 percent, respectively [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seborrheic dermatitis of the face, trunk, and intertriginous areas
         </strong>
         – The prevention of relapse of seborrheic dermatitis of the face, trunk, and intertriginous areas has not been well studied. However, it is common practice to use antifungal cream or
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo (as facial or body wash) intermittently (once or twice weekly) to prevent relapse. The risk of side effects with this approach is minimal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intermittent use of topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (eg, twice weekly) may be an alternative to topical antifungal agents as a long-term maintenance treatment for severe facial seborrheic dermatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small, randomized trial, 114 adult patients with severe seborrheic dermatitis of the face initially treated with a topical corticosteroid for seven days received twice-weekly treatment with
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.1% ointment or ciclopiroxolamine 1% cream until relapse and up to 24 weeks [
         <a href="#rid38">
          38
         </a>
         ]. The median time to first relapse was 92 days (range 15 to 195 days) in the tacrolimus group versus 27 days (range 13 to 201 days) in the ciclopiroxolamine group. However, more treatment-related adverse effects, defined as burning, pruritus, and erythema, occurred in patients in the tacrolimus group than in those in the
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         group.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H827171841">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116474.html" rel="external">
          "Society guideline links: Seborrheic dermatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13010789">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/82948.html" rel="external">
          "Patient education: Seborrheic dermatitis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/7636.html" rel="external">
          "Patient education: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1666197">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and clinical presentation
         </strong>
         – Seborrheic dermatitis is a chronic, relapsing form of dermatitis occurring in areas rich in sebaceous glands (scalp, face, upper trunk, intertriginous areas). The mildest and most common form of scalp seborrheic dermatitis is dandruff, presenting with diffuse scaliness of the scalp  (
         <a class="graphic graphic_picture graphicRef54173" href="/z/d/graphic/54173.html" rel="external">
          picture 2
         </a>
         ). Severe forms present with inflamed, erythematous plaques covered with yellowish, greasy scales  (
         <a class="graphic graphic_picture graphicRef76985 graphicRef114660 graphicRef114661 graphicRef59104 graphicRef65167 graphicRef53407" href="/z/d/graphic/76985.html" rel="external">
          picture 1C, 1E, 3A-D
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and differential diagnosis
         </strong>
         – The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. The differential diagnosis includes psoriasis  (
         <a class="graphic graphic_picture graphicRef115750" href="/z/d/graphic/115750.html" rel="external">
          picture 4
         </a>
         ), rosacea  (
         <a class="graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083" href="/z/d/graphic/77020.html" rel="external">
          picture 7A-E
         </a>
         ), tinea versicolor  (
         <a class="graphic graphic_picture graphicRef78860" href="/z/d/graphic/78860.html" rel="external">
          picture 8
         </a>
         ), pityriasis rosea  (
         <a class="graphic graphic_picture graphicRef87126 graphicRef87124" href="/z/d/graphic/87126.html" rel="external">
          picture 9A-B
         </a>
         ), tinea corporis  (
         <a class="graphic graphic_picture graphicRef76839" href="/z/d/graphic/76839.html" rel="external">
          picture 10
         </a>
         ), secondary syphilis, lupus erythematosus  (
         <a class="graphic graphic_picture graphicRef64844 graphicRef75833" href="/z/d/graphic/64844.html" rel="external">
          picture 11A-B
         </a>
         ), and pemphigus foliaceous  (
         <a class="graphic graphic_picture graphicRef60530 graphicRef54341" href="/z/d/graphic/60530.html" rel="external">
          picture 12A-B
         </a>
         ). These conditions can be differentiated clinically and/or through laboratory tests and histology. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Seborrheic dermatitis is a chronic condition. The main goal of therapy is to clear the visible signs of the disease and reduce associated symptoms. Repeated treatment or long-term maintenance treatment is often necessary  (
         <a class="graphic graphic_algorithm graphicRef141494" href="/z/d/graphic/141494.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141495" href="/z/d/graphic/141495.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Scalp
         </strong>
         <strong>
          dermatitis
         </strong>
         – For patients with mild, noninflammatory seborrheic dermatitis of the scalp (dandruff), we suggest antifungal shampoos (
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2%,
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1%) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative antifungal shampoos available over the counter include
         <a class="drug drug_general" data-topicid="10237" href="/z/d/drug information/10237.html" rel="external">
          zinc pyrithione
         </a>
         1% and
         <a class="drug drug_general" data-topicid="9885" href="/z/d/drug information/9885.html" rel="external">
          selenium sulfide
         </a>
         2.5%. Shampoo should be used daily or at least two or three times per week until remission is achieved. (See
         <a class="local">
          'Seborrheic dermatitis of the scalp'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with moderate to severe, inflammatory seborrheic dermatitis of the scalp, we suggest antifungal shampoos (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo) in combination with a high-potency topical corticosteroid  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ) in a formulation (lotion, spray, foam) of the patient's choice (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The topical corticosteroid can be used once daily for two weeks. (See
         <a class="local">
          'Seborrheic dermatitis of the scalp'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Facial
         </strong>
         <strong>
          dermatitis
         </strong>
         – For patients with seborrheic dermatitis of the face, we suggest low-potency topical corticosteroids (groups 6 or 7  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )), topical antifungal agents  (
         <a class="graphic graphic_table graphicRef76148" href="/z/d/graphic/76148.html" rel="external">
          table 2
         </a>
         ), or a combination of the two (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In patients with mild dermatitis with minimal erythema and pruritus, we prefer treatment with topical antifungals alone. In patients with marked erythema and pruritus, we typically start treatment with a low-potency topical corticosteroid once or twice daily until symptoms subside or up to two weeks and then switch to topical antifungals as maintenance treatment. Topical corticosteroids can be used intermittently in case of flare-up. Topical calcineurin inhibitors (
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.1% ointment and
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         1% cream),
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         2% cream, and
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          roflumilast
         </a>
         0.3% foam may be alternatives to topical corticosteroids for facial seborrheic dermatitis, as they lack the local adverse effects of topical corticosteroids (eg, skin atrophy, telangiectasias). (See
         <a class="local">
          'Seborrheic dermatitis of the face'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with seborrheic dermatitis of the face who have mustaches and beards, we suggest
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampooing of the facial hair (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The shampoo is used daily until remission and then once per week. A low-potency corticosteroid (group 7  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) can be added to the initial treatment to control inflammation and itching.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Trunk/intertriginous areas
         </strong>
         – For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with low-potency topical corticosteroid cream (groups 6 or 7  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )), topical antifungal agents, or a combination of the two (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Medium-potency topical corticosteroids (groups 4 or 5) can be used for seborrheic dermatitis involving the chest or the upper back. We typically start treatment with topical corticosteroids once or twice daily until symptoms subside and then switch to topical antifungals. (See
         <a class="local">
          'Seborrheic dermatitis of the trunk and intertriginous areas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of relapse
         </strong>
         – For most patients with seborrheic dermatitis, intermittent use of topical therapies may be helpful to prevent relapse. (See
         <a class="local">
          'Prevention of relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo or
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         1% shampoo once per week for seborrheic dermatitis of the scalp (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         2% shampoo (as facial or body wash) or ketoconazole 2% cream once per week for seborrheic dermatitis of the face, trunk, and intertriginous areas (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Other topical azoles or
         <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">
          ciclopirox
         </a>
         can be used as alternatives to topical ketoconazole  (
         <a class="graphic graphic_table graphicRef76148" href="/z/d/graphic/76148.html" rel="external">
          table 2
         </a>
         ).
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Johnson ML. Skin Conditions and Related Need for Medical Care among Persons 1–74 Years, United States, 1971–1974. Series 11, Data from the National Health Survey November, No. 212, DHEW Pub No. (PHS) 79–1660. U.S. Department of Health, Education, and Welfare, Public Health Service, National Center for Health, Hyattsville, MD 1978.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger RS, Stoner MF, Hobbs ER, et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol 1986; 14:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JL, Cartlidge M, Shuster S. Effect of L-dopa on the seborrhoea of Parkinsonism. Br J Dermatol 1973; 88:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn SR, Pochi PE, Strauss JS, et al. Sebaceous gland secretion in Parkinson's disease during L-dopa treatment. J Invest Dermatol 1973; 60:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed) 1983; 286:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975; 64:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amado Y, Patiño-Uzcátegui A, Cepero de García MC, et al. Seborrheic dermatitis: predisposing factors and ITS2 secondary structure for Malassezia phylogenic analysis. Med Mycol 2013; 51:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SY, Kim SH, Kim SN, et al. Isolation and identification of Malassezia species from Chinese and Korean patients with seborrheic dermatitis and in vitro studies on their bioactivity on sebaceous lipids and IL-8 production. Mycoses 2016; 59:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pechère M, Krischer J, Remondat C, et al. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol 1999; 26:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandström Falk MH, Tengvall Linder M, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 2005; 85:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arsic Arsenijevic VS, Milobratovic D, Barac AM, et al. A laboratory-based study on patients with Parkinson's disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatol 2014; 14:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulino LC. New perspectives on dandruff and seborrheic dermatitis: lessons we learned from bacterial and fungal skin microbiota. Eur J Dermatol 2017; 27:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faergemann J, Bergbrant IM, Dohsé M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riciputo RM, Oliveri S, Micali G, Sapuppo A. Phospholipase activity in Malassezia furfur pathogenic strains. Mycoses 1996; 39:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adalsteinsson JA, Kaushik S, Muzumdar S, et al. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol 2020; 29:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz-Pérez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osei-Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. Clin Exp Dermatol 2010; 35:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ljubojevic S, Lipozencic J, Basta-Juzbasic A. Contact allergy to corticosteroids and Malassezia furfur in seborrhoeic dermatitis patients. J Eur Acad Dermatol Venereol 2011; 25:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverberg JI, Hou A, Warshaw EM, et al. Allergens in patients with a diagnosis of seborrheic dermatitis, North American Contact Dermatitis Group data, 2001-2016. J Am Acad Dermatol 2022; 86:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okokon EO, Verbeek JH, Ruotsalainen JH, et al. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev 2015; :CD008138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apasrawirote W, Udompataikul M, Rattanamongkolgul S. Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis. J Med Assoc Thai 2011; 94:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl 1:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piérard-Franchimont C, Piérard GE, Vroome V, et al. Comparative anti-dandruff efficacy between a tar and a non-tar shampoo. Dermatology 2000; 200:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman WJ. Carcinogenicity of coal-tar shampoo. Lancet 1995; 345:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol 2012; 67:e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol 2012; 5:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Tejedor I, Tetart F, et al. Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study. J Am Acad Dermatol 2021; 84:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2009; 20:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Versteeg SG. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol 2017; 18:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osborne GE, Taylor C, Fuller LC. The management of HIV-related skin disease. Part II: neoplasms and inflammatory disorders. Int J STD AIDS 2003; 14:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballanger F, Tenaud I, Volteau C, et al. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res 2008; 300:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol 2002; 12:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. Efalith Multicenter Trial Group. J Am Acad Dermatol 1992; 26:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev 2014; :CD009446.
          </a>
         </li>
         <li class="breakAll">
          Roflumilast topical foam, 0.3%. US Food and Drug Administration (FDA) approved product information. Revised December 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217242s000lbl.pdf (Accessed on January 05, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zirwas MJ, Draelos ZD, DuBois J, et al. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial. JAMA Dermatol 2023; 159:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peña SM, Oak ASW, Smith AM, et al. Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 2020; 34:e809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol 2014; 28:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McFalda WL, Roebuck HL. Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: a case report. J Clin Aesthet Dermatol 2011; 4:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope E, Kowalski E, Tausk F. Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis. JAAD Case Rep 2022; 24:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132:441.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13669 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Johnson ML. Skin Conditions and Related Need for Medical Care among Persons 1–74 Years, United States, 1971–1974. Series 11, Data from the National Health Survey November, No. 212, DHEW Pub No. (PHS) 79–1660. U.S. Department of Health, Education, and Welfare, Public Health Service, National Center for Health, Hyattsville, MD 1978.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2971687" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cutaneous manifestations of early human immunodeficiency virus exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2936776" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4268445" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effect of L-dopa on the seborrhoea of Parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4699650" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sebaceous gland secretion in Parkinson's disease during L-dopa treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6220754" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Seborrhoea is not a feature of seborrhoeic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/237965" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1694869" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23947747" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Seborrheic dermatitis: predisposing factors and ITS2 secondary structure for Malassezia phylogenic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26786542" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Isolation and identification of Malassezia species from Chinese and Korean patients with seborrheic dermatitis and in vitro studies on their bioactivity on sebaceous lipids and IL-8 production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11446527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10535248" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Malassezia spp carriage in patients with seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15848985" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24628775" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A laboratory-based study on patients with Parkinson's disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28690211" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : New perspectives on dandruff and seborrheic dermatitis: lessons we learned from bacterial and fungal skin microbiota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260013" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8909036" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Phospholipase activity in Malassezia furfur pathogenic strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9767239" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23806151" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32125725" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : An update on the microbiology, immunology and genetics of seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2934444" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Seborrheic dermatitis in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19164189" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical practice. Seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764146" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19874370" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Immune reconstitution inflammatory syndrome involving the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6195866" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Seborrhoeic dermatitis of the face induced by PUVA treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20854306" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Contact allergy to corticosteroids and Malassezia furfur in seborrhoeic dermatitis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34582838" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Allergens in patients with a diagnosis of seborrheic dermatitis, North American Contact Dermatitis Group data, 2001-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25933684" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Topical antifungals for seborrhoeic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21696088" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15655141" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8245236" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271196" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10773717" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Comparative anti-dandruff efficacy between a tar and a non-tar shampoo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7837890" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Carcinogenicity of coal-tar shampoo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22101215" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22142161" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33010323" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17188780" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16924062" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18677657" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27804089" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678527" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12716492" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The management of HIV-related skin disease. Part II: neoplasms and inflammatory disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18330588" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459525" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1532964" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. Efalith Multicenter Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24838779" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24838779" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37133856" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32452557" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23802806" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Systematic review of oral treatments for seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21278898" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35619595" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7718463" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
